Impact Factor 3.508
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

Correction ARTICLE

Front. Neurol., 13 June 2018 | https://doi.org/10.3389/fneur.2018.00416

Corrigendum: Amino Acids in Cerebrospinal Fluid of Patients With Aneurysmal Subarachnoid Haemorrhage: An Observational Study

Bartosz Sokół1*, Bartosz Urbaniak2, Norbert Wąsik1, Szymon Plewa2, Agnieszka Klupczyńska2, Roman Jankowski1, Barbara Więckowska3, Robert Juszkat4 and Zenon Kokot2
  • 1Department of Neurosurgery, Poznan University of Medical Sciences, Poznan, Poland
  • 2Faculty of Pharmacy, Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Poznan, Poland
  • 3Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland
  • 4Department of General and Interventional Radiology, Poznan University of Medical Sciences, Poznan, Poland

A corrigendum on
Amino Acids in Cerebrospinal Fluid of Patients with Aneurysmal Subarachnoid Haemorrhage: An Observational Study

by Sokół, B., Urbaniak, B., Wasik, N., Plewa, S., Klupczynska, A., Jankowski, R., et al. (2017). Front. Neurol. 8:438. doi: 10.3389/fneur.2017.00438

In the original article, there were mistakes in Table 2, Table 3, Table 4, Figure 1, Figure 2, Figure 3 and Figure 4.

In all mentioned tables and figures, quantity of amino acids was described in mM instead of μM. The corrected tables and figures appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

TABLE 2
www.frontiersin.org

Table 2. Differences in CSF amino acid level at day 0-3, 5, and 10 post-SAH in healthy individuals (control group) and SAH patients (study group).

TABLE 3
www.frontiersin.org

Table 3. Differences in monitored parameters at day 0-3, 5, and 10 post-SAH in patients with good (GO-SAH) and poor (PO-SAH) treatment outcome.

TABLE 4
www.frontiersin.org

Table 4. Amino acid level changes in time in good outcome SAH patients with (GO-SAH).

FIGURE 1
www.frontiersin.org

Figure 1. Significant differences in monitored parameters on day 0–3 post-SAH between patients with good (GO-SAH) and poor (PO-SAH) treatment outcome. Mann–Whitney test revealed significantly higher levels of: (A) taurine (p = 0.038), (B) aspartic acid (p = 0.038), (C) citruline (p = 0.035), (D) glutamic acid (p = 0.038), (E) 3-methylhistidine (p < 0.01), (F) gamma-aminobutyric acid (p = 0.043), (G) ornithine (p = 0.033), (H) cystathionine (p < 0.01), (I) isoleucine (p = 0.045) in patients with poor outcome. T-Student test revealed significantly higher level of white blood cell count (p < 0.01) in patients with poor outcome (J). In all cases median levels and the 25th and 75th percentile are presented.

FIGURE 2
www.frontiersin.org

Figure 2. Significant differences in monitored parameters on day 5 post-SAH between patients with good (GO-SAH) and poor (PO-SAH) treatment outcome. (A) T-Student test revealed significantly higher levels of glutamic acid (p = 0.041) in patients with poor outcome. Mann–Whitney test revealed significantly higher C-reactive protein level (p = 0.020) (B) and white blood cell count (p = 0.044) (C) in patients with poor outcome. In all cases median levels and the 25th and 75th percentile are presented.

FIGURE 3
www.frontiersin.org

Figure 3. Significant differences in monitored parameters on day 10 post-SAH between patients with good (GO-SAH) and poor (PO-SAH) treatment outcome. Mann–Whitney test revealed significantly higher 2-aminoadipic acid (p = 0.033) (A) and fibrinogen (p = 0.014) (B) levels in patients with poor outcome. Median levels and the 25th and 75th percentile are presented.

FIGURE 4
www.frontiersin.org

Figure 4. Scatter charts showing the correlation between treatment outcome (measured by Glasgow outcome scale at 3 months) and other parameters. Spearman's test revealed significant correlations (cc > 0.6 or cc < −0.6) for: (A) 2-aminoadipic acid on day 10 post-SAH (cc = −0.81), (B,C) cystathionine on day 5 post-SAH (cc = −0.72) and day 10 post-SAH (cc = −0.67), (D) 3-methylhistidine on day 0–3 post-SAH (cc = −0.64), (E) o-phosphoethanolamine on day 10 post-SAH (cc = −0.62), (F) World Federation of Neurosurgical Societies scale (cc = −0.64), (G) Hunt and Hess scale (cc = −0.61), (H) Glasgow coma scale (cc = 0.72), (I,J) C-reactive protein on day 5 post-SAH (cc = −0.64) and day 10 post-SAH (cc = −0.79), (K) Fibrinogen on day 10 post-SAH (cc = −0.97). P-values are <0.05 in all cases.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: subarachnoid haemorrhage, amino acids, early brain injury, delayed cerebral ischaemia, biomarkers

Citation: Sokół B, Urbaniak B, Wąsik N, Plewa S, Klupczyńska A, Jankowski R, Więckowska B, Juszkat R and Kokot Z (2018) Corrigendum: Amino Acids in Cerebrospinal Fluid of Patients With Aneurysmal Subarachnoid Haemorrhage: An Observational Study. Front. Neurol. 9:416. doi: 10.3389/fneur.2018.00416

Received: 03 May 2018; Accepted: 22 May 2018;
Published: 13 June 2018.

Edited and reviewed by: J. Marc Simard, University of Maryland, Baltimore, United States

Copyright © 2018 Sokół, Urbaniak, Wąsik, Plewa, Klupczyńska, Jankowski, Więckowska, Juszkat and Kokot. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Bartosz Sokół, bartosz.sokol@ump.edu.pl